Synairgen (SNG) RNS Announcements

Add to Alert list
Date Time Source Announcement
23 Feb 2007 03:16 PM
RNS
Holding(s) in Company
13 Feb 2007 04:40 PM
RNS
Notice of Results
12 Dec 2006 11:55 AM
RNS
Total Voting Rights
30 Nov 2006 03:18 PM
RNS
Director/PDMR Shareholding
15 Nov 2006 03:41 PM
RNS
Result of AGM
15 Nov 2006 07:00 AM
RNS
Licenses novel Peptide
08 Nov 2006 11:11 AM
RNS
Holding(s) in Company
08 Nov 2006 10:21 AM
RNS
Director/PDMR Shareholding
18 Sep 2006 07:00 AM
RNS
Final Results
01 Sep 2006 07:00 AM
RNS
Notice of Results
14 Aug 2006 07:00 AM
RNS
Licensing Agreement
24 May 2006 07:00 AM
RNS
Research Update
11 Apr 2006 12:55 PM
RNS
Directorate Change
23 Feb 2006 07:00 AM
RNS
Interim Results
16 Jan 2006 11:00 AM
RNS
Notice of Results
16 Nov 2005 03:40 PM
RNS
Director/PDMR Shareholding
15 Nov 2005 12:15 PM
RNS
Result of AGM
15 Nov 2005 07:00 AM
RNS
Interferon-Beta Enters Clinic
14 Nov 2005 07:00 AM
RNS
Change of Adviser
27 Sep 2005 07:00 AM
RNS
Final Results
06 Sep 2005 09:00 AM
RNS
Notice of Results
13 Jul 2005 11:18 AM
RNS
Holding(s) in Company
22 Mar 2005 07:35 AM
RNS
Published Research
22 Mar 2005 07:00 AM
RNS
Published Research
18 Mar 2005 11:43 AM
RNS
Holding(s) in Company
09 Mar 2005 07:00 AM
RNS
Collaboration with Centocor
09 Mar 2005 07:00 AM
RNS
Interim Results
28 Feb 2005 12:00 PM
RNS
Notice of Results
04 Nov 2004 09:27 AM
RNS
Holding(s) in Company

Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic.

Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections.

Synairgen share price launched at 155p in 2004.

UK 100

Latest directors dealings